Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects that have a confirmed diagnosis of RRMS, as per the 2010 revised McDonald criteria
Subjects satisfying the therapeutic indication of natalizumab, as described in the local product label and confirmed by the Investigator. (Patients with previous treatment with natalizumab are also considered to be eligible only if the last natalizumab infusion was at least 1 year before the screening visit of this study)
Decision for a treatment with natalizumab has been made before screening
Patients with an EDSS score of 2.0-5.5 (both limits inclusive)
You may not be if
Patients with a diagnosed co-existing brain pathology other than MS, which in the judgement of the investigator impacts the value of EDSS or QoL.
Pure spinal manifestation of demyelination
Diagnosis of primary or secondary progressive MS
Any change in concomitant medication known to affect cognition or bladder function
A history of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse, as assessed by the Investigator
